International audiencePolygenic hazard score (PHS) models are associated with age at diagnosis of prostate cancer. Our model developed in Europeans (PHS46) showed reduced performance in men with African genetic ancestry. We used a cross-validated search to identify single nucleotide polymorphisms (SNPs) that might improve performance in this population. Anonymized genotypic data were obtained from the PRACTICAL consortium for 6253 men with African genetic ancestry. Ten iterations of a 10-fold cross-validation search were conducted to select SNPs that would be included in the final PHS46+African model. The coefficients of PHS46+African were estimated in a Cox proportional hazards framework using age at diagnosis as the dependent variable and...
BackgroundWe previously developed an African-ancestry-specific polygenic hazard score (PHS46+African...
Background We previously developed an African-ancestry-specific polygenic hazard score (PHS46+Africa...
Genetic models for cancer have been evaluated using almost exclusively European data, which could ex...
International audiencePolygenic hazard score (PHS) models are associated with age at diagnosis of pr...
International audiencePolygenic hazard score (PHS) models are associated with age at diagnosis of pr...
International audiencePolygenic hazard score (PHS) models are associated with age at diagnosis of pr...
International audiencePolygenic hazard score (PHS) models are associated with age at diagnosis of pr...
International audiencePolygenic hazard score (PHS) models are associated with age at diagnosis of pr...
Polygenic hazard score (PHS) models are associated with age at diagnosis of prostate cancer. Our mod...
Polygenic hazard score (PHS) models are associated with age at diagnosis of prostate cancer. Our mod...
Polygenic hazard score (PHS) models are associated with age at diagnosis of prostate cancer. Our mod...
Polygenic hazard score (PHS) models are associated with age at diagnosis of prostate cancer. Our mod...
International audienceBackground: We previously developed an African-ancestry-specific polygenic haz...
BackgroundWe previously developed an African-ancestry-specific polygenic hazard score (PHS46+African...
BackgroundWe previously developed an African-ancestry-specific polygenic hazard score (PHS46+African...
BackgroundWe previously developed an African-ancestry-specific polygenic hazard score (PHS46+African...
Background We previously developed an African-ancestry-specific polygenic hazard score (PHS46+Africa...
Genetic models for cancer have been evaluated using almost exclusively European data, which could ex...
International audiencePolygenic hazard score (PHS) models are associated with age at diagnosis of pr...
International audiencePolygenic hazard score (PHS) models are associated with age at diagnosis of pr...
International audiencePolygenic hazard score (PHS) models are associated with age at diagnosis of pr...
International audiencePolygenic hazard score (PHS) models are associated with age at diagnosis of pr...
International audiencePolygenic hazard score (PHS) models are associated with age at diagnosis of pr...
Polygenic hazard score (PHS) models are associated with age at diagnosis of prostate cancer. Our mod...
Polygenic hazard score (PHS) models are associated with age at diagnosis of prostate cancer. Our mod...
Polygenic hazard score (PHS) models are associated with age at diagnosis of prostate cancer. Our mod...
Polygenic hazard score (PHS) models are associated with age at diagnosis of prostate cancer. Our mod...
International audienceBackground: We previously developed an African-ancestry-specific polygenic haz...
BackgroundWe previously developed an African-ancestry-specific polygenic hazard score (PHS46+African...
BackgroundWe previously developed an African-ancestry-specific polygenic hazard score (PHS46+African...
BackgroundWe previously developed an African-ancestry-specific polygenic hazard score (PHS46+African...
Background We previously developed an African-ancestry-specific polygenic hazard score (PHS46+Africa...
Genetic models for cancer have been evaluated using almost exclusively European data, which could ex...